Innovation Pharmaceuticals to Discuss Recent Positive Clinical Results in IBD and Upcoming Milestones in Oral Mucositis and Psoriasis Trials at BioCentury’s “NewsMakers” Conference

BEVERLY, MA – August 15, 2017 (GLOBE NEWSWIRE) Innovation Pharmaceuticals, (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announced that the Company will present a corporate overview at BioCentury’s 24th Annual NewsMakers in the Biotech Industry Conference at the Millennium Broadway Hotel in New York, NY.

The presentation is scheduled for 2:30 pm (EDT) on Friday, September 8, 2017 in Room 302/303. A corresponding presentation slide deck will be made available under the Events and Presentations section of the Company website following the event.

"BioCentury’s NewsMakers conference is a great opportunity for us to share our recent positive clinical trial results regarding Brilacidin treatment of ulcerative proctitis/proctosigmoiditis (two types of Inflammatory Bowel Disease; IBD). We will also highlight the major events upcoming for us in the fourth quarter, namely anticipated completion of our Phase 2 trials of Brilacidin-OM for oral mucositis and Prurisol for psoriasis,” commented Leo Ehrlich, Chief Executive Officer at Innovation Pharmaceuticals. “These trials will provide perspectives as to how our drug candidates might progress toward tremendous market opportunities, as there is a need for a preventative medicine for oral mucositis and a new oral drug for psoriasis to challenge the current treatments. BioCentury established this conference as a premier venue for highlighting companies with upcoming milestones by putting them in front of analysts and institutional money managers. With next steps for our IBD program in planning and the conclusions of the Brilacidin-OM and Prurisol studies approaching, the event is particularly relevant for us in keeping the investment community current in our drug development programs.”